Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EBMT 2022 | State of the art in CML

Guillermo Ortí • 21 Mar 2022
EBMT 2022
Chronic Myeloid Leukemia Leukemia

Guillermo Ortí, MD, PhD, Vall d’Hebron Institute of Oncology, Barcelona, Spain, summarizes current treatment strategies for patients with chronic myeloid leukemia (CML). The frontline management of CML consists of tyrosine kinase inhibitors (TKIs), and patients who relapse usually undergo allogeneic hematopoietic stem cell transplantation (alloHSCT). Patients with CML who progress to accelerated phase (AP) receive alloHSCT while patients who progress to blast phase (AP) are treated with TKIs or alloHSCT if they do not respond to TKIs. This interview took place at the 48th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT) 2022, which was held virtually.

More from Guillermo Ortí

1:39
Emerging therapeutic approaches for TKI-resistant CML
Guillermo Ortí • 21 Mar 2022
1:08
Latest advances in BP-MPNs
Guillermo Ortí • 21 Mar 2022
1:23
Current status of alloHSCT in BP-MPNs
Guillermo Ortí • 21 Mar 2022
1:23
PTCy in unrelated and haploidentical donor alloHSCT in CML
Guillermo Ortí • 21 Mar 2022

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals